250 related articles for article (PubMed ID: 18174260)
1. Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta.
Galliher-Beckley AJ; Schiemann WP
Carcinogenesis; 2008 Feb; 29(2):244-51. PubMed ID: 18174260
[TBL] [Abstract][Full Text] [Related]
2. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.
Galliher AJ; Schiemann WP
Cancer Res; 2007 Apr; 67(8):3752-8. PubMed ID: 17440088
[TBL] [Abstract][Full Text] [Related]
3. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells.
Galliher AJ; Schiemann WP
Breast Cancer Res; 2006; 8(4):R42. PubMed ID: 16859511
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Wendt MK; Schiemann WP
Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
[TBL] [Abstract][Full Text] [Related]
5. p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity.
Wendt MK; Smith JA; Schiemann WP
J Biol Chem; 2009 Dec; 284(49):34145-56. PubMed ID: 19822523
[TBL] [Abstract][Full Text] [Related]
6. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of pro-alpha(1)(I) collagen by TGF-beta(1) in mesangial cells: role of the p38 MAPK pathway.
Chin BY; Mohsenin A; Li SX; Choi AM; Choi ME
Am J Physiol Renal Physiol; 2001 Mar; 280(3):F495-504. PubMed ID: 11181412
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells.
Shinto O; Yashiro M; Kawajiri H; Shimizu K; Shimizu T; Miwa A; Hirakawa K
Br J Cancer; 2010 Mar; 102(5):844-51. PubMed ID: 20145621
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.
Wendt MK; Smith JA; Schiemann WP
Oncogene; 2010 Dec; 29(49):6485-98. PubMed ID: 20802523
[TBL] [Abstract][Full Text] [Related]
10. Role of transforming growth factor (TGF)-beta Type I and TGF-beta type II receptors in the TGF-beta1-regulated gene expression in pituitary prolactin-secreting lactotropes.
Sarkar DK; Pastorcic M; De A; Engel M; Moses H; Ghasemzadeh MB
Endocrinology; 1998 Aug; 139(8):3620-8. PubMed ID: 9681516
[TBL] [Abstract][Full Text] [Related]
11. The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta.
Sokol JP; Neil JR; Schiemann BJ; Schiemann WP
Breast Cancer Res; 2005; 7(5):R844-53. PubMed ID: 16168131
[TBL] [Abstract][Full Text] [Related]
12. Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II.
Maeda M; Shintani Y; Wheelock MJ; Johnson KR
J Biol Chem; 2006 Jan; 281(1):59-68. PubMed ID: 16267045
[TBL] [Abstract][Full Text] [Related]
13. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.
Park CY; Min KN; Son JY; Park SY; Nam JS; Kim DK; Sheen YY
Cancer Lett; 2014 Aug; 351(1):72-80. PubMed ID: 24887560
[TBL] [Abstract][Full Text] [Related]
14. Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β.
Parvani JG; Galliher-Beckley AJ; Schiemann BJ; Schiemann WP
Mol Biol Cell; 2013 Nov; 24(21):3449-59. PubMed ID: 24006485
[TBL] [Abstract][Full Text] [Related]
15. TGF-beta control of cell proliferation.
Huang SS; Huang JS
J Cell Biochem; 2005 Oct; 96(3):447-62. PubMed ID: 16088940
[TBL] [Abstract][Full Text] [Related]
16. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
17. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.
Muraoka RS; Dumont N; Ritter CA; Dugger TC; Brantley DM; Chen J; Easterly E; Roebuck LR; Ryan S; Gotwals PJ; Koteliansky V; Arteaga CL
J Clin Invest; 2002 Jun; 109(12):1551-9. PubMed ID: 12070302
[TBL] [Abstract][Full Text] [Related]
18. Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.
Horie K; Yamashita H; Mogi A; Takenoshita S; Miyazono K
J Cell Physiol; 1998 Jun; 175(3):305-13. PubMed ID: 9572475
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis.
Siegel PM; Shu W; Cardiff RD; Muller WJ; Massagué J
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8430-5. PubMed ID: 12808151
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the functional binding sites for TGF-beta on the type II receptor leads to suppression of TGF-beta signaling.
Shimanuki T; Hara T; Furuya T; Imamura T; Miyazono K
Oncogene; 2007 May; 26(23):3311-20. PubMed ID: 17146441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
